Key Highlights

  • Bridgeline Digital (NASDAQ:BLIN): up 20.77 percent to USD 0.7971; USD 3.95 million at-the-market program.
  • Atrium Therapeutics (NASDAQ:RNA): up 15.84 percent to USD 9.58; USD 50 million private Placement priced October 8, 2026.
  • ZJK Industrial (NASDAQ:ZJK): up 8.70 percent to USD 1.50; USD 9.8 million share program in place.
  • Agape ATP (NASDAQ:ATPC): down 6.21 percent to USD 1.36; planned unit offering and Going Concern doubt.
  • Jiade (NASDAQ:JDZG): down 28.67 percent to USD 0.6678 after a volatile week.
  • Dominari Holdings (NASDAQ:DOMH): up 7.93 percent to USD 1.77; USD 5 million repurchase program.

Bridgeline Digital (NASDAQ:BLIN): A Jump With No Fresh Headline

Bridgeline Digital (NASDAQ:BLIN) was up 20.77 percent to USD 0.7971 in pre-market trading on November 2, 2026. No announcement dated that day was identified, so the catalyst is not confirmed.

A prospectus supplement dated July 14, 2026 allows sales of up to USD 3.95 million of common stock through an at-the-market program, with no minimum sale required. Cash was approximately USD 1.0 million at fiscal year end, and the shares are now below USD 1 after the company regained Nasdaq bid price compliance in June 2026.

Atrium Therapeutics (NASDAQ:RNA): Trading Above the Placement Price

Atrium Therapeutics (NASDAQ:RNA) was up 15.84 percent to USD 9.58 in pre-market trading on November 2, 2026. No announcement dated that day was identified; the nearest news was an October 27, 2026 release on the first patient dosed in a Phase 1/2 trial of ATR 1072.

On October 8, 2026, the company priced a private placement of about USD 50 million at USD 7.93 per share, and the pre-market price is about 20.8 percent higher (calculated). An investor letter made public on October 20, 2026 asked for an explanation of the dilutive financing. Initial proof-of-concept data is expected in the second half of 2027.

ZJK Industrial (NASDAQ:ZJK): A Rebound With a Share Program in Place

ZJK Industrial (NASDAQ:ZJK) was up 8.70 percent to USD 1.50 in pre-market trading on November 2, 2026. No announcement dated that day was identified, and the bounce appears to follow a decline of about 31.7 percent over the prior month.

A Form 6-K dated August 3, 2026 set up an at-the-market program of up to USD 9.8 million of Class A ordinary shares, with no shares sold at that time. First-half 2026 Revenue rose 36.60 percent to USD 33.74 million, while gross Margin slipped to 42.35 percent from 49.87 percent. A filing dated October 19, 2026 disclosed a proposed sale of 553,222 shares by a holder.

Agape ATP (NASDAQ:ATPC): A Dip With a Going Concern Warning

Agape ATP (NASDAQ:ATPC) was down 6.21 percent to USD 1.36 in pre-market trading on November 2, 2026. No announcement explaining the move was identified. The shares closed at USD 1.61 on October 29, 2026, so the pre-market price is about 15.5 percent lower (calculated).

A Form 10-Q filed on August 14, 2026 flagged going concern doubt, and an amended registration statement filed on July 20, 2026 describes a planned offering of stock and Warrant units. Fiscal 2025 revenue was USD 1.5 million with a net loss of USD 2.3 million, and the company completed a 1-for-50 reverse split earlier this year.

Jiade (NASDAQ:JDZG): A Steep Drop After Wild Swings

Jiade (NASDAQ:JDZG) was down 28.67 percent to USD 0.6678 in pre-market trading on November 2, 2026. No company announcement explaining the move was identified. On October 28, 2026, market data showed the shares opening near USD 6.30 and touching a low near USD 1.17.

The company completed an initial public offering that raised USD 8 million. Revenue for 2025 was about RMB 25.7 million, roughly USD 3.7 million, according to its annual report, with about 0.93 million shares outstanding (calculated).

Dominari Holdings (NASDAQ:DOMH): Edging Higher With a Repurchase Program

Dominari Holdings (NASDAQ:DOMH) was up 7.93 percent to USD 1.77 in pre-market trading on November 2, 2026. The implied prior close is about USD 1.64 (calculated). No announcement dated late October or November 2, 2026 was identified.

On September 17, 2026, the board authorised a share repurchase program of up to USD 5 million. First-half 2026 revenue was USD 52.6 million, up 14 percent, though second quarter revenue fell to USD 16.8 million from USD 38.9 million. The company has completed direct offerings earlier in its history, and Capital raises could dilute holders.

Where Things Stand

These six stocks all carry offering, financing or share Supply questions, from at-the-market programs at Bridgeline and ZJK to a planned unit offering at Agape ATP and a recent placement at Atrium. Only Atrium had company news within the past week, and none had an announcement dated November 2, 2026 identified. Watch for sales under the at-the-market programs, the response to the Atrium investor letter, share count changes at Jiade and the next quarterly filings.